secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-09-28T21:03:44+00:00
Accession:  0002007919-26-000050
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Inhibrx Biosciences posts updated investor presentation to website; exhibit text truncated with no new data disclosed
--------------------------------------------------------------------------------

- Inhibrx Biosciences (INBX) said it posted an updated corporate presentation to the 'Investors' tab of www.inhibrx.com on September 28, 2026.
- The 8-K provides no financial results, guidance, clinical data or deal terms; only the presentation's title slide and forward-looking-statements disclaimer are included in the filing text.
- Filing signed by Chief Financial Officer Kelly Deck, dated September 28, 2026; company is a Delaware corporation headquartered at 11025 N. Torrey Pines Road, La Jolla, CA.
- Because the exhibit content is not readable here, no specific updates to pipeline, cash runway or trial timelines can be confirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000050/0002007919-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000050/inhibrx-20260928.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer